From natural phages to personalized approaches and infection prevention & control. Explore the progress of each development pathway.
DEVELOPMENT PATHWAY / 01
NatPhages
Research direction and background
NatPhages targets the most prevalent, multidrug-resistant and hard-to-treat superbugs in clinical settings, including Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa and Staphylococcus aureus . Leveraging CreatiPhage's high-quality library of native lytic phages and phenotypic database of phage-bacteria interactions, representative phages are carefully selected to formulate a native phage cocktail featuring broad coverage and low propensity to induce bacterial tolerance, for new biologics application.
CPD-PA01Clinical-IITR&DPre-ClinicalClinical-IITClinical-ISTCommercialization
Pseudomonas aeruginosa is one of the most clinically threatening and drug-resistant pathogens, ranking second among the 12 superbugs most urgently in need of antimicrobials (World Health Organization, 2017). In 2022, more than 420,818 cases of P. aeruginosa infections were detected in Chinese medical institutions, with a 16.6% drug resistance rate to carbapenems (CRPA).
The phage library of P. aeruginosa at CreatiPhage is characterized by high quality, comprehensive information, and broad intra-specie coverage. Therefore, CPD-PA01 is a natural phage cocktail that broadly targets clinically prevalent strains of drug-resistant P. aeruginosa. It is in liquid form and indicated for wound infections. In preclinical studies, it demonstrated broad-spectrum bactericidal activity against P. aeruginosa isolates associated with wound and pulmonary infections, with a favorable animal safety profile. An investigator-initiated phase 1/2 randomized controlled clinical trial conducted in collaboration with partner institutions has now completed patient enrollment.
CPD-AB01Pre-ClinicalR&DPre-ClinicalClinical-IITClinical-ISTCommercialization
Acinetobacter baumannii accounts for over 400,000 related deaths annually worldwide, ranking first among 12 superbugs (World Health Organization, 2017). In China, 220,000 cases of Acinetobacter baumannii infections were detected in healthcare facilities in 2020, 53.7% of which were resistant to carbapenem antibiotics (CRAB), with no new antibiotics available.
CreatiPhage's A. baumannii phage library is of high quality, with comprehensive information and wide strain coverage. The CPD-AB01, a natural phage cocktail covering drug-resistant strains, is currently undergoing preclinical studies. The initial pipeline is indicated for lung infections, with the phage formulation being a liquid administered via inhalation.